Genflow Biosciences Plc

GENF

Equity

ISIN GB00BP2C3V08 / Valor 115917310

LSE London Stock Exchange, SETS (2026-03-26)

GBP 0.018%

Genflow Biosciences Plc
UMushroom community rating:

3.00 2 votes No rating yet

NegativeNeutralPositive

About company

Genflow Biosciences plc (LON:GENF, OTCQB:GENFF) is a UK-based biotechnology company focused on developing therapeutics aimed at slowing or halting the aging process in humans and dogs. With research and development facilities located in Belgium and a commercial office in Cambridge, Massachusetts, Genflow leverages its proprietary approach centered on the SIRT6 gene, specifically utilizing a centenarian variant that has shown promising results in preclinical studies. The company collaborates with prestigious institutions such as the University of Rochester, Columbia University, and Albert Einstein College of Medicine, holding an exclusive license for its core therapeutic platform. Genflow is advancing its SIRT6-related patent in Japan, a key market due to its rapidly aging population, positioning the company as a leader in the longevity gene therapy sector. Led by an experienced management team from the pharmaceutical and biotechnology industries, Genflow aims to continue progressing its development programs over the next two years.

Summarized from source with an LLMView SourceSector: Technology

Xuhan Tu

United Kingdom, 26 Oct 2025

Risk

Cherie Ngai

United Kingdom, 26 Oct 2025

Genflow is an early=stage biotech with promising longetivity research, but performance has been limited due to vlatility and high R&D costs. Strong innovation potential, though commercial success and societal impact remain uncertain.

EQUITIES OF THE SAME SECTOR

Santhera Pharmaceuticals Holding Ltd.